Form 8-K - Current report:
SEC Accession No. 0001193125-25-050880
Filing Date
2025-03-10
Accepted
2025-03-10 16:11:58
Documents
14
Period of Report
2025-03-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d937334d8k.htm   iXBRL 8-K 25528
5 GRAPHIC g937334g0307220505900.jpg GRAPHIC 2721
  Complete submission text file 0001193125-25-050880.txt   155567

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250305.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250305_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250305_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d937334d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 25723810
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)